A post-80s girl uses targeted drugs to fight lung cancer. Instead of worrying about drug resistance, she opts for a new type of adjuvant therapy

时间：2026-04-27　人气：

If you find it difficult to understand the subsequent professional descriptions, you can quickly read through this text in two minutes.

Ms. Y, born in the 1980s, was diagnosed with lung cancer during her career ascension, when her children were still young and she had elderly family members to take care of. At this age, when she was the "pillar of the family", Ms. Y not only had to focus entirely on the treatment of her disease, but also had to face the challenge of balancing work, family, and life with her husband.

The treatment for cancer is long and mentally demanding. Patients in their prime often have to give up their jobs and spend years in the hospital with the company of their family members, which can be even more distressing. However, after choosing NKT cell immunotherapy, Ms. Y not only achieved good results but also freed herself from the time-consuming and mentally exhausting treatment, successfully balancing the relationship between treatment, work, and family.

Disease Overview:

In October 2017, Ms. Y underwent a chest X-ray that revealed a nodule in the upper lobe of her right lung. She underwent surgery and the postoperative pathology showed: (upper right) invasive moderately differentiated adenocarcinoma with EGFR gene exon 19 deletion mutation. After surgery, she received four cycles of conventional chemotherapy, using pemetrexed combined with cisplatin.

However, the stability was only maintained for two years. In July 2019, a follow-up examination revealed new lesions in her right lung, suggesting metastasis. This time, the targeted drug afatinib was used, and although the lesions shrank, Ms. Y experienced significant adverse reactions during the treatment - ulcers, rashes, and diarrhea.

Although the targeted drug temporarily inhibited the growth of metastatic lesions, Ms. Y remained worried because in the pathological classification of malignant tumors, the lower the differentiation degree, the worse the prognosis. Ms. Y had moderately differentiated adenocarcinoma, which carries a higher risk. The recurrence that had already occurred left Ms. Y with lingering fears, not only because the side effects of the targeted drug made her feel overwhelmed but also because there was a possibility of drug resistance and eventual failure.

Ms. Y hopes to find a treatment method that can prevent future recurrence and metastasis, is not resistant to drugs, and does not require a lot of time and effort.

Through a friend's recommendation, Ms. Y contacted Professor Zhang Minghui's team at Tsinghua University School of Medicine. After analysis, the professor suggested the following treatment plan for Ms. Y:

1) Use precision radiotherapy to locally treat the recurrent lesion, followed by NKT cell therapy to maintain long-term systemic stability. Simultaneously, radiotherapy combined with immunotherapy has the best "abscopal effect";

2) Postpone targeted therapy, but if there are signs of tumor activity, use targeted drugs for periodic suppression, while maintaining NKT cell therapy to prolong the drug-resistant period.

3) NKT therapy does not require a lot of time and effort, and has basically no side effects, making it very friendly to patients and addressing Ms. Y's concerns.

From November 2019 to August 2021, Ms. Y completed 21 months of NKT cell therapy. During this period, three follow-up examinations showed no obvious signs of tumor progression, and the overall evaluation reached 21 months of stability!

Imaging Findings:

Multiple imaging reviews have shown no significant changes in the size of the nodules under the pleura of the right lung, and no significant changes in the size of the small nodules in the right lung.

Tumor Markers:

Tumor markers: From November 2019 to August 2021, CEA, NSE, and CYFRA21-1 were all within the normal range . Follow-up is recommended to closely monitor any changes.

Quality of Life:

During nearly two years of treatment, Ms. Y's physical condition has significantly improved. She reports fewer colds and fever during spring and winter, her hair has become thicker and smoother, and her skin is fairer and more ruddy. She has not missed work, and her quality of life is excellent, with a score of 78.5.

Conclusion:

Ms. Y achieved her expected treatment goals by adopting the method of precision radiotherapy combined with NKT cell therapy, and successfully addressed her need to balance work and family care.

Nearly two years have passed, and the latest assessment results remain stable with no progression. NKT therapy has achieved excellent tumor control for Ms. Y.

Let's look forward to the follow-up presentation next year.

NKT Classic Case Review

Click on the image

to view

上一篇：不按常理出牌，肺癌术后五年不复发不转移，因为用了这种方法

下一篇：肺癌术后连续复发2次，换种新方法，终于让癌细胞不“回头”

About Lehe

Corporate Culture Founder's Introduction Lehe News Story of Lehe Science Popularization Academic Literature

New Medical Services

Second Consultation Rehabilitation and Wellness Elite Care

Oncology Clinical Research

Lung Cancer Stomach Cancer Hepatobiliary and Pancreatic Cancers Intestine Cancer Breast Cancer B-cell lymphoma Cervical Cancer Other Solid Tumors

Chronic Disease Research

Hypertension Diabetes Obesity Immune Diseases Degenerative Diseases Chronic Inflammation Others

Contact Us

Address: Room 1101 (Unit 101), 11th Floor, Building 1, No. 7 Courtyard, Kexueyuan Road, Life Science Park, Changping District, Beijing
Phone：010-8265 9866
Email：lehemedneo@hotmail.com

Copyright©2022 Beijing Lehe New Medical Clinic Co., Ltd. All Rights Reserved ICP: 京ICP备2025148232号京公网安备11011402054997号 Privacy Policy